Sonia Garg1, James A de Lemos2, Susan A Matulevicius2, Colby Ayers2, Ambarish Pandey2, Ian J Neeland2, Jarett D Berry2, Roderick McColl2, Christopher Maroules2, Ronald M Peshock2, Mark H Drazner2. 1. From the Division of Cardiology, Department of Internal Medicine (S.G., J.A.d.L., S.A.M., A.P., I.J.N., J.D.B., M.H.D.), Department of Clinical Science (C.A., J.D.B.), and Department of Radiology (R.M., C.M., R.M.P.), University of Texas Southwestern Medical Center, Dallas. sonia.garg@utsouthwestern.edu. 2. From the Division of Cardiology, Department of Internal Medicine (S.G., J.A.d.L., S.A.M., A.P., I.J.N., J.D.B., M.H.D.), Department of Clinical Science (C.A., J.D.B.), and Department of Radiology (R.M., C.M., R.M.P.), University of Texas Southwestern Medical Center, Dallas.
Abstract
BACKGROUND: In the conventional paradigm of the progression of left ventricular hypertrophy, a thick-walled left ventricle (LV) ultimately transitions to a dilated cardiomyopathy. There are scant data in humans demonstrating whether this transition occurs commonly without an interval myocardial infarction. METHODS AND RESULTS: Participants (n=1282) from the Dallas Heart Study underwent serial cardiac magnetic resonance ≈7 years apart. Those with interval cardiovascular events and a dilated LV (increased LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded. Multivariable linear regression models tested the association of concentric hypertrophy (increased LV mass and LV mass/volume0.67) with change in LVEDV. The study cohort had a median age of 44 years, 57% women, 43% black, and 11% (n=142) baseline concentric hypertrophy. The change in LVEDV in those with versus without concentric hypertrophy was 1 mL (-9 to 12) versus -2 mL (-11 to 7), respectively, P<0.01. In multivariable linear regression models, concentric hypertrophy was associated with larger follow-up LVEDV (P≤0.01). The progression to a dilated LV was uncommon (2%, n=25). CONCLUSIONS: In the absence of interval myocardial infarction, concentric hypertrophy was associated with a small, but significantly greater, increase in LVEDV after 7-year follow-up. However, the degree of LV enlargement was minimal, and few participants developed a dilated LV. These data suggest that if concentric hypertrophy does progress to a dilated cardiomyopathy, such a transition would occur over a much longer timeframe (eg, decades) and perhaps less common than previously thought. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00344903.
BACKGROUND: In the conventional paradigm of the progression of left ventricular hypertrophy, a thick-walled left ventricle (LV) ultimately transitions to a dilated cardiomyopathy. There are scant data in humans demonstrating whether this transition occurs commonly without an interval myocardial infarction. METHODS AND RESULTS:Participants (n=1282) from the Dallas Heart Study underwent serial cardiac magnetic resonance ≈7 years apart. Those with interval cardiovascular events and a dilated LV (increased LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded. Multivariable linear regression models tested the association of concentric hypertrophy (increased LV mass and LV mass/volume0.67) with change in LVEDV. The study cohort had a median age of 44 years, 57% women, 43% black, and 11% (n=142) baseline concentric hypertrophy. The change in LVEDV in those with versus without concentric hypertrophy was 1 mL (-9 to 12) versus -2 mL (-11 to 7), respectively, P<0.01. In multivariable linear regression models, concentric hypertrophy was associated with larger follow-up LVEDV (P≤0.01). The progression to a dilated LV was uncommon (2%, n=25). CONCLUSIONS: In the absence of interval myocardial infarction, concentric hypertrophy was associated with a small, but significantly greater, increase in LVEDV after 7-year follow-up. However, the degree of LV enlargement was minimal, and few participants developed a dilated LV. These data suggest that if concentric hypertrophy does progress to a dilated cardiomyopathy, such a transition would occur over a much longer timeframe (eg, decades) and perhaps less common than previously thought. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00344903.
Authors: Aya J Alame; Sonia Garg; Julia Kozlitina; Colby Ayers; Ronald M Peshock; Susan A Matulevicius; Mark H Drazner Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Christopher W Puleo; Colby R Ayers; Sonia Garg; Ian J Neeland; Alana A Lewis; Ambarish Pandey; Mark H Drazner; James A de Lemos Journal: Biomark Med Date: 2021-10-19 Impact factor: 2.851
Authors: Julia Kozlitina; Sonia Garg; Mark H Drazner; Susan A Matulevicius; Colby Ayers; John Overton; Jeffrey Reid; Aris Baras; Krishnasree Rao; Ambarish Pandey; Jarett Berry; James A de Lemos; Justin L Grodin Journal: J Card Fail Date: 2021-10-09 Impact factor: 5.712
Authors: Michinari Hieda; Satyam Sarma; Christopher M Hearon; James P MacNamara; Katrin A Dias; Mitchel Samels; Dean Palmer; Sheryl Livingston; Margot Morris; Benjamin D Levine Journal: Circulation Date: 2021-09-20 Impact factor: 39.918
Authors: Fernando U Kay; Suhny Abbara; Parag H Joshi; Sonia Garg; Amit Khera; Ronald M Peshock Journal: Circ Cardiovasc Imaging Date: 2020-02-18 Impact factor: 7.792
Authors: Michinari Hieda; Satyam Sarma; Christopher M Hearon; Katrin A Dias; Jose Martinez; Mitchel Samels; Braden Everding; Dean Palmer; Sheryl Livingston; Margot Morris; Erin Howden; Benjamin D Levine Journal: Circulation Date: 2019-12-23 Impact factor: 29.690
Authors: Andrea Barbieri; Alessandro Albini; Anna Maisano; Gerardo De Mitri; Giovanni Camaioni; Niccolò Bonini; Francesca Mantovani; Giuseppe Boriani Journal: Front Cardiovasc Med Date: 2021-04-27
Authors: Elizabeth D Luczak; Yuejin Wu; Jonathan M Granger; Mei-Ling A Joiner; Nicholas R Wilson; Ashish Gupta; Priya Umapathi; Kevin R Murphy; Oscar E Reyes Gaido; Amin Sabet; Eleonora Corradini; Wen-Wei Tseng; Yibin Wang; Albert J R Heck; An-Chi Wei; Robert G Weiss; Mark E Anderson Journal: Nat Commun Date: 2020-09-04 Impact factor: 14.919
Authors: Neela D Thangada; Kershaw V Patel; Bradley Peden; Vijay Agusala; Julia Kozlitina; Sonia Garg; Mark H Drazner; Colby Ayers; Jarett D Berry; Ambarish Pandey Journal: J Am Heart Assoc Date: 2021-02-22 Impact factor: 5.501
Authors: Bryan Wilner; Sonia Garg; Colby R Ayers; Christopher D Maroules; Roderick McColl; Susan A Matulevicius; James A de Lemos; Mark H Drazner; Ronald Peshock; Ian J Neeland Journal: J Am Heart Assoc Date: 2017-07-19 Impact factor: 5.501